Featured Research

from universities, journals, and other organizations

Incontinence Treatment: Muscle-derived Stem Cells Prove Effective In Reparing Sphincter Damage To Restore Continence

Date:
May 17, 2008
Source:
American Urological Association
Summary:
Transplantation of muscle-derived stem cells may provide a safe and effective treatment for patients suffering from urinary incontinence following a surgical procedure. Patients with incontinence resulting from iatrogenic sphincter damage may benefit from this therapy.

Transplantation of muscle-derived stem cells may provide a safe and effective treatment for patients suffering from urinary incontinence following a surgical procedure. Two studies presented at the 103rd Annual Scientific Meeting of the American Urological Association (AUA), show that patients with incontinence resulting from iatrogenic sphincter damage may benefit from this therapy. Researchers are from Germany and Austria.

Certain medical procedures, including transurethral resection of the prostate and radical prostatectomy can result in damage to the external urinary sphincter. In one study, a German research team successfully implanted muscle cells grown from tissue from the patients’ deltoid muscles into the damaged sphincter.

One year later, four patients were completely continent and 19 patients had improved from grade III to grade I incontinence. With more than half of the patients experiencing an improvement in continence after four months, the use of muscle-derived cells to repair sphincter damage proved successful. Minor side effects were observed in five patients.

A second study reaffirmed these findings. Using muscle cells from the upper arms of 65 incontinent men who had undergone a prostatectomy, researchers in Austria grew the cells in a laboratory and then implanted them. Patients were evaluated before the surgery to define their level of incontinence and evaluated post-operatively to monitor complications.

Prior to therapy, the mean number of pads used per day was 4.89, and after treatment, the mean number of pads decreased to 1.59. 27.9 percent of patients did not wear pads at all and 43.6 percent reported that they only required a pad for “special occasions.” Only 28.5 percent of patients still required pads.


Story Source:

The above story is based on materials provided by American Urological Association. Note: Materials may be edited for content and length.


Journal References:

  1. Otto T, Eimer C, Gerullis H: Repair of iatrogenic sphincter damage and urinary incontinence by autologous skeletal muscle derived http://dx.doi.org/10.1016/S0022-5347(08)61422-6cells (MDC). J Urol, suppl., 2008; 179: 484, abstract 1414. [link]
  2. Strasser H, Mitterberger M, Dalpiaz O, Kerschbaumer A, Pinggera GM, Frauscher F et al: Transurethral ultrasound guided injection of autologous myo- and fibroblasts in treatment of incontinence in men: 2 year data. J Urol, suppl., 2008; 179: 483, abstract 1413. [link]

Cite This Page:

American Urological Association. "Incontinence Treatment: Muscle-derived Stem Cells Prove Effective In Reparing Sphincter Damage To Restore Continence." ScienceDaily. ScienceDaily, 17 May 2008. <www.sciencedaily.com/releases/2008/05/080515072735.htm>.
American Urological Association. (2008, May 17). Incontinence Treatment: Muscle-derived Stem Cells Prove Effective In Reparing Sphincter Damage To Restore Continence. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2008/05/080515072735.htm
American Urological Association. "Incontinence Treatment: Muscle-derived Stem Cells Prove Effective In Reparing Sphincter Damage To Restore Continence." ScienceDaily. www.sciencedaily.com/releases/2008/05/080515072735.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins